Please Wait...

Jeffrey Heilbraun

Translation skills

Main profile

Jeffrey Heilbraun
Sr. Director Medical and Scientific Affairs

Jeffrey Heilbraun attended Tufts University in Boston, Massachusetts where he completed his Bachelor of Science degree in Biology with a focus on physiology. Jeff continued his studies at The American University in Washington D.C., receiving a fellowship and completing his Masters of Science in Health Promotion and Disease Management. He was employed at The American University as an adjunct professor in the Health Promotion program. Throughout his career, Jeff has maintained his focus on the science, technology,  trial design and regulatory considerations surrounding  cardiac safety (ECG and blood pressure endpoints) within pharmaceutical development, with a special interest in hemodynamics. Jeff has presented posters and session participation at the Drug Information Association (DIA) meeting, American Society of Hypertension (ASH), and at the Cardiac Safety Research Consortium (CSRC).  He has supported publications in cardiac safety considerations in Oncology drug development and the regulatory considerations for “off-target” blood pressure response in compound development.

 

Register Now
 
 
 

 

Authored Publications

Sager P, Heilbraun J, Turner JR, Gintant G, Geiger MJ, Kowey PR, Mansoor GA, Mendzelevski B, Michelson EL, Stockbridge N, Weber MA, White WB. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J. 2013 Apr;165(4):477-88. doi: 10.1016/j.ahj.2013.01.002.

Braddock M, Heilbraun J, Mendzelevski B. Cardiovascular safety and hemodynamic considerations in oncology drug development -- webinar highlights October 10th 2012Expert Opin Drug Saf. 2013 Sep;12(5):783-91. doi: 10.1517/14740338.2013.797407. Epub 2013 May 8. PMID: 23651420

Blogs

If you are in clinical development and interested in latest developments in cardiac safety blood pressure (BP) requirements, I encourage you to attend a public workshop announced by the U.S. Food and Drug Administration (FDA) entitled "Evaluating the Pressor Effects of Drugs & Ambulatory Blood Pressure Monitoring Studies." This workshop is convened by the Duke-Robert J.

Blood pressure monitor

— Part 2 in a 3-part blog series on cardiac safety regulatory developments

Thanks to scientific advancements and increased understanding of pathways and systems that contribute to cardiac risk, the cardiac safety ECG environment continues to mature and expand. Presently, the assessment of QT/QTc from the electrocardiogram is the primary focal endpoint in cardiac safety.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/CA1LnzLZBs
Bioclinica (4 hours ago)
In our latest blog post, we review the "burdens" of #CTMS implementation - and how better solutions address them.… https://t.co/vcyS2gvwpu
Bioclinica (5 days ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/01liAxqx0J
Bioclinica (6 days ago)
Rapid implementation. Increased control & efficiency. Out-of-the-box configuration. Turn-key validation. Cost savin… https://t.co/XO53jwd2DV
Bioclinica (2 weeks ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/ZtxVWMlznP
Bioclinica (2 weeks ago)
Bioclinica's #IRT uses an agile delivery methodology, which means flexible configuration and customization, and del… https://t.co/SRd2uNscWc
Bioclinica (2 weeks ago)